Gain Therapeutics Statistics
Total Valuation
GANX has a market cap or net worth of $113.35 million. The enterprise value is $105.14 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, before market open.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
GANX has 36.10 million shares outstanding. The number of shares has increased by 54.44% in one year.
| Current Share Class | 36.10M |
| Shares Outstanding | 36.10M |
| Shares Change (YoY) | +54.44% |
| Shares Change (QoQ) | +15.35% |
| Owned by Insiders (%) | 3.71% |
| Owned by Institutions (%) | 12.03% |
| Float | 34.76M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 19.12 |
| P/TBV Ratio | 19.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.52, with a Debt / Equity ratio of 0.10.
| Current Ratio | 2.52 |
| Quick Ratio | 2.30 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -261.72% and return on invested capital (ROIC) is -135.80%.
| Return on Equity (ROE) | -261.72% |
| Return on Assets (ROA) | -86.79% |
| Return on Invested Capital (ROIC) | -135.80% |
| Return on Capital Employed (ROCE) | -258.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$775,670 |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, GANX has paid $1.30 million in taxes.
| Income Tax | 1.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.53% in the last 52 weeks. The beta is 0.13, so GANX's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | +72.53% |
| 50-Day Moving Average | 2.13 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 69.69 |
| Average Volume (20 Days) | 1,230,621 |
Short Selling Information
The latest short interest is 1.78 million, so 4.93% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short Previous Month | 910,705 |
| Short % of Shares Out | 4.93% |
| Short % of Float | 5.12% |
| Short Ratio (days to cover) | 1.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | -8.95M |
| Operating Income | -17.59M |
| Pretax Income | -18.10M |
| Net Income | -19.39M |
| EBITDA | -17.55M |
| EBIT | -17.59M |
| Earnings Per Share (EPS) | -$0.64 |
Full Income Statement Balance Sheet
The company has $8.81 million in cash and $605,278 in debt, giving a net cash position of $8.20 million or $0.23 per share.
| Cash & Cash Equivalents | 8.81M |
| Total Debt | 605,278 |
| Net Cash | 8.20M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 5.91M |
| Book Value Per Share | 0.16 |
| Working Capital | 6.35M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$17.30 million and capital expenditures -$945, giving a free cash flow of -$17.30 million.
| Operating Cash Flow | -17.30M |
| Capital Expenditures | -945 |
| Free Cash Flow | -17.30M |
| FCF Per Share | -$0.48 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GANX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -54.44% |
| Shareholder Yield | -54.44% |
| Earnings Yield | -17.11% |
| FCF Yield | -15.27% |
Analyst Forecast
The average price target for GANX is $8.00, which is 154.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.00 |
| Price Target Difference | 154.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |